Treating Pseudomonas: How Does Ceftolozane-Tazobactam Differ from Other Beta-Lactams?
AUG 09, 2017 | CONTAGION® EDITORIAL STAFF
Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains how ceftolozane-tazobactam differs from other beta-lactams for treating Pseudomonas infections.
Interview Transcript (slightly modified for readability)
“What’s different about ceftolozane-tazobactam is that when you compare it to the other beta-lactams that have activity against Pseudomonas, the 3 main mechanisms of resistance that will knock out those agents, this drug is stable to. So, what’s really nice about it, and what makes it different, is that it can retain activity even in the setting of resistance [compared with] our traditional agents; it makes it a nice option from that standpoint.” DISCLOSURES: Jason Pogue is a Consultant for Merck, Allergan, Med Co, Shionogi, Zavante, Achaogen. This study was supported by a grant from Merck.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512